Cannabidiol for the treatment of psychosis in Parkinson's disease.
about
Does Cannabidiol Protect Against Adverse Psychological Effects of THC?Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disordersMetabolic syndrome: an important risk factor for Parkinson's diseaseCannabinoid receptor CB1 mediates baseline and activity-induced survival of new neurons in adult hippocampal neurogenesisCannabidiol, among Other Cannabinoid Drugs, Modulates Prepulse Inhibition of Startle in the SHR Animal Model: Implications for Schizophrenia PharmacotherapyProtective effects of cannabidiol on lesion-induced intervertebral disc degenerationSelf-reported efficacy of cannabis and other complementary medicine modalities by Parkinson's disease patients in colorado.Effects of cannabinoid drugs on the deficit of prepulse inhibition of startle in an animal model of schizophrenia: the SHR strainEndocannabinoid system and psychiatry: in search of a neurobiological basis for detrimental and potential therapeutic effects.Inverted U-Shaped Dose-Response Curve of the Anxiolytic Effect of Cannabidiol during Public Speaking in Real Life.Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report.Drug-induced psychosis: how to avoid star gazing in schizophrenia research by looking at more obvious sources of light.Current Status and Prospects for Cannabidiol Preparations as New Therapeutic Agents.Cannabidiol as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stress.The therapeutic potential of cannabinoids for movement disorders.Cannabinoid modulation of functional connectivity within regions processing attentional salience.Safety and pharmacokinetics of oral cannabidiol when administered concomitantly with intravenous fentanyl in humansCannabinoids and Dementia: A Review of Clinical and Preclinical Data.Cannabinoids and Schizophrenia: Risks and Therapeutic PotentialCan oral fluid cannabinoid testing monitor medication compliance and/or cannabis smoking during oral THC and oromucosal Sativex administration?Cannabidiol Prevents Motor and Cognitive Impairments Induced by Reserpine in RatsSplendor in the Grass? A Pilot Study Assessing the Impact of Medical Marijuana on Executive Function.The 3rd Schizophrenia International Research Society Conference, 14-18 April 2012, Florence, Italy: summaries of oral sessions.Marijuana Compounds: A Nonconventional Approach to Parkinson's Disease Therapy.The role of phytochemicals in the treatment and prevention of dementia.Endocannabinoid system dysfunction in mood and related disorders.Medicinal plants and dementia therapy: herbal hopes for brain aging?What can we learn about schizophrenia from studying the human model, drug-induced psychosis?The role of cannabinoids and leptin in neurological diseases.An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies.Even High Doses of Oral Cannabidol Do Not Cause THC-Like Effects in Humans: Comment on Merrick et al. Cannabis and Cannabinoid Research 2016;1(1):102-112; DOI: 10.1089/can.2015.0004.The Use of Cannabinoids in Treating Dementia.Modulation of cognitive and emotional processing by cannabidiol: the role of the anterior cingulate cortex.Cannabinoids for the Treatment of Movement Disorders.Cannabinoids in Parkinson's DiseaseEffects of cannabidiol on amphetamine-induced oxidative stress generation in an animal model of mania.Effects of acute systemic administration of cannabidiol on sleep-wake cycle in rats.Effects of cannabidiol in the treatment of patients with Parkinson's disease: an exploratory double-blind trial.Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson's disease patients: a case series.Sub-chronic impact of cannabinoids in street cannabis on cognition, psychotic-like symptoms and psychological well-being.
P2860
Q21129107-82E41490-19CE-4B05-A55D-678F65C45617Q24623179-A8B97F14-46D1-40C7-9517-DAC02FD440E1Q27023711-15857150-9203-49B3-A928-6482D82864BBQ27497540-6C2CAF51-FFBB-4C9F-BC9D-44BC9BADDF8EQ28078534-D314F23A-EB42-4F14-A65C-0817FFC70021Q28542740-BCA449D5-A631-4991-9B07-E04F5BF0B29FQ30373216-DE345FFB-6298-4F59-B456-556B077A4FBBQ30442731-EA25324C-2C11-4CCE-A132-42C56F3D328AQ30473707-C42DD9C3-4606-49AD-89AC-EA216B810E54Q33658933-B63C457D-FAEE-4768-94D1-5F41C004213CQ34137084-63F5D587-AACD-4633-B05F-E55B2F718D56Q34509725-8CCDE53C-F3B8-4628-89D5-17D630BD11BFQ34530386-8420188C-ECA9-4AB6-B710-3D76158D3D7DQ34898890-1D9DD307-813D-4D54-A6A8-B4C4991F5061Q35171113-F2CD2FED-B99E-4F1C-8161-8F998D7533D1Q35420974-59A20FC6-6997-4C48-A979-0761CD0B83E3Q35665889-150B36B9-6845-4458-9C7B-7C7BA2FD9627Q36155898-31062C83-8606-452A-8D44-6D9443186AE5Q36157669-C5FC4AAB-755B-4FA8-9275-39CC75A3C2E4Q36729404-D15868C0-4B81-4098-9549-E0E778EE0BB8Q37292275-502E4220-3451-425B-9096-C6117949BB4FQ37336806-2476CF8D-0AE8-4A64-B4FF-375DAED3C8E0Q37425054-615A63AC-F995-4212-941A-00D2E74C802CQ37512670-34249BC5-2931-4E02-9635-AB0CD47B6DFCQ37884566-240B6608-65D7-4CAA-8438-5771B1C3AA8CQ37932017-C925478A-BFB4-49C3-95F2-5C65DC49E6E5Q37954368-6F529BF5-C389-449D-A9A5-77ADA65CF40DQ38153344-C9B48F55-4D6E-4579-9FCB-D3453471A96DQ38423817-FF5770C1-66BF-4A47-86FA-BCCF1089F8AFQ38598487-2BFB3EDA-9FE6-44F2-8681-2728CDC088ECQ38598503-C9A292F4-156B-4104-A9E0-2B8B0AF5DA81Q39385097-90180FC4-9A6B-42CD-9A33-8C340B2C1303Q39919107-02B80BDF-68CC-4B61-B68A-784721B92EADQ40701861-5CD31112-D3C9-4ECB-BA8A-7452F10A1472Q42258332-CC8CFCDA-7D83-42A2-B119-101D4AB6CE7DQ43235417-627C69B4-68C6-483B-978A-2294BE61F252Q44205288-ECE92323-CB46-4B1B-881A-5A17EB294146Q48065074-14A6B9B7-5ACC-4A6F-8FC0-22F5B269F7AEQ48105623-B1A979E6-8A82-41D6-ABCC-9433634B3540Q48821406-8B5E7013-1597-4F70-97A0-24B428AFC73D
P2860
Cannabidiol for the treatment of psychosis in Parkinson's disease.
description
2008 nî lūn-bûn
@nan
2008 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Cannabidiol for the treatment of psychosis in Parkinson's disease.
@ast
Cannabidiol for the treatment of psychosis in Parkinson's disease.
@en
Cannabidiol for the treatment of psychosis in Parkinson's disease.
@nl
type
label
Cannabidiol for the treatment of psychosis in Parkinson's disease.
@ast
Cannabidiol for the treatment of psychosis in Parkinson's disease.
@en
Cannabidiol for the treatment of psychosis in Parkinson's disease.
@nl
altLabel
Cannabidiol for the treatment of psychosis in Parkinson’s disease
@en
prefLabel
Cannabidiol for the treatment of psychosis in Parkinson's disease.
@ast
Cannabidiol for the treatment of psychosis in Parkinson's disease.
@en
Cannabidiol for the treatment of psychosis in Parkinson's disease.
@nl
P2093
P2860
P921
P356
P1476
Cannabidiol for the treatment of psychosis in Parkinson's disease.
@en
P2093
A W Zuardi
G G R Rodrigues
J A S Crippa
J E C Hallak
M H N Chagas
S M Dursun
P2860
P304
P356
10.1177/0269881108096519
P407
P577
2008-09-18T00:00:00Z